PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Get Free Report) CEO Larry Wood bought 23,900 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the transaction, the chief executive officer directly owned 23,900 shares in the company, valued at approximately $498,315. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
PROCEPT BioRobotics Stock Up 5.4%
Shares of NASDAQ:PRCT opened at $22.89 on Wednesday. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -11.80 and a beta of 0.89. PROCEPT BioRobotics Corporation has a 12 month low of $16.67 and a 12 month high of $42.71. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $21.39 and a 200 day moving average price of $24.63.
PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The company had revenue of $94.50 million for the quarter, compared to the consensus estimate of $92.77 million. During the same period in the previous year, the firm earned ($0.35) earnings per share. The company’s revenue was up 19.3% compared to the same quarter last year. As a group, equities research analysts predict that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current year.
PROCEPT BioRobotics News Summary
- Positive Sentiment: CEO Larry Wood purchased 23,900 shares at an average price of $20.85, investing approximately $498,315. The open-market purchase may signal that management views the stock as undervalued and could provide some investor confidence. SEC insider transaction filing
- Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior period, with a zero-day days-to-cover ratio. Because the figures appear anomalous and include an undefined percentage change, they provide little useful evidence about current short-selling pressure.
- Negative Sentiment: Multiple law firms publicized a securities class action against PROCEPT and reminded investors of a September 22, 2026 deadline to seek lead-plaintiff status for purchases made from February 28, 2024, through February 25, 2026. The repeated notices keep litigation risk in focus, although they are not new findings of wrongdoing. Kaplan Fox class action notice
- Negative Sentiment: The allegations concern potentially misleading disclosures about product demand, weaker-than-expected handpiece sales and excess customer inventory allegedly created by late-quarter bulk discounts. One law-firm announcement linked those issues to an approximately 18% stock decline. If substantiated, the claims could lead to legal costs, management distraction, reputational damage and pressure on future sales. Bleichmar Fonti securities lawsuit announcement
Analyst Ratings Changes
PRCT has been the topic of several recent research reports. William Blair lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Truist Financial set a $21.00 price objective on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Jefferies Financial Group reiterated a “hold” rating and set a $20.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Robert W. Baird set a $20.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Finally, Evercore set a $23.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, PROCEPT BioRobotics currently has a consensus rating of “Hold” and an average target price of $28.00.
View Our Latest Research Report on PRCT
Institutional Investors Weigh In On PROCEPT BioRobotics
A number of institutional investors and hedge funds have recently modified their holdings of PRCT. Baillie Gifford & Co. grew its holdings in shares of PROCEPT BioRobotics by 18.3% in the fourth quarter. Baillie Gifford & Co. now owns 1,015,978 shares of the company’s stock worth $31,963,000 after purchasing an additional 157,147 shares during the last quarter. B. Metzler seel. Sohn & Co. AG bought a new stake in PROCEPT BioRobotics during the 4th quarter valued at about $1,864,000. DNB Asset Management AS lifted its holdings in PROCEPT BioRobotics by 213.9% during the 4th quarter. DNB Asset Management AS now owns 99,567 shares of the company’s stock valued at $3,132,000 after buying an additional 67,848 shares in the last quarter. Pinnacle Associates Ltd. purchased a new stake in PROCEPT BioRobotics in the 4th quarter valued at about $3,876,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in PROCEPT BioRobotics by 69.8% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 174,739 shares of the company’s stock valued at $5,375,000 after buying an additional 71,832 shares during the period. 89.46% of the stock is owned by institutional investors.
PROCEPT BioRobotics Company Profile
PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.
The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.
Featured Articles
- Five stocks we like better than PROCEPT BioRobotics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
